In this episode of #AskDrDurie, IMF Chairman Dr. Brian Durie offers his take on whether or not maintenance is recommended for a patient who has already achieved a stringent complete remission (SCR) with his or her myeloma.

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
Can polio or other viruses treat myeloma?
Next Post
When will the first monoclonal antibody be approved?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.